Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors, particularly in targeted cancer therapies. It plays a critical role in the development of tyrosine kinase inhibitors (TKIs) that are designed to treat non-small cell lung cancer (NSCLC) and other solid tumors. The compound’s structure allows for selective binding and inhibition of mutant forms of EGFR, including T790M and L858R, which are associated with tumor progression and resistance to earlier generations of drugs. Due to its ability to cross the blood-brain barrier, derivatives based on this scaffold are also explored for treating brain metastases in cancer patients. Its application in medicinal chemistry focuses on optimizing potency, selectivity, and pharmacokinetic properties in next-generation oncology drugs.